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RSelection Bias in “Prognostic
Impact of Staged Versus
‘One-Time’ Multivessel
Percutaneous Intervention in
Acute Myocardial Infarction”
Kornowski et al. (1) should be commended for attempting to
validate the current guidelines regarding staged versus “one-time”
stenting in the setting of an acute ST-segment elevation myocar-
dial infarction. Their recent article in the Journal was a prespecified
econdary analysis of the HORIZONS-AMI (Harmonizing Out-
omes With Revascularization and Stents in Acute Myocardial
nfarction) cohort.
Given the high likelihood of measured and nonmeasured
aseline differences between the groups who received multivessel
tenting in either a staged or “one-time” fashion, the researchers
ook pains to limit confounding through multivariate and propen-
ity score modeling. Unfortunately, such modeling cannot account
or the patients who had multivessel coronary disease but were
ever included in this analysis because they developed contraindi-
ations (e.g., renal failure or neurological complications) to repeat
ercutaneous coronary intervention (PCI) or died before a second
CI attempt. This survival-based selection bias clearly favors the
taged approach by excluding patients in the HORIZONS-AMI
rial with multivessel disease who received only culprit artery
tenting because they did not survive long enough (or well enough)
o have their other lesions treated. Figures 2 and 3 of their paper
1) corroborated that the majority of deaths in the “one-time”
roup happened within the first few days of the index event.
eanwhile, the median time between first and second PCI events
n the staged group was 30 days later (range 6 to 51 days).
The analysis presented by Kornowski et al. (1) corroborated the
urrent American Heart Association/American College of Cardi-
logy Class III Level of Evidence: B guidelines that “PCI should
ot be performed in a noninfarct artery at the time of primary PCI
n patients without hemodynamic compromise.” Although the
uidelines are clear, there have been discordant, albeit potentially
awed, results in recent published reports regarding this practice
2,3), and it remains more common than might be explained by
ardiogenic shock alone (4). Unfortunately, the selection bias
nherent to the study by Kornowski et al. (1) may have limited its
bility to definitively settle any lingering questions about “one-
ime” multivessel stenting in the setting of an AMI without
emodynamic compromise. A report on the total number of
atients with multivessel coronary disease at the time of primary
ngiography in the HORIZONS-AMI trial and their outcomes
lassified by number of vessels stented (1 vs. 1) and timing
staged vs. “one time”) of their PCI would help us understand how
uch selection bias affected the reported results.*James M. McCabe, MD
Ehrin J. Armstrong, MD
*Brigham and Women’s Hospital
75 Francis Street
Boston, Massachusetts 02115
E-mail: mccabe@aya.yale.edu
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Reply
We thank Drs. McCabe and Armstrong for their valuable comment
in regards to our paper (1). In general, we tend to agree with them but
also want to mention that we clearly stated in the article that despite
the best propensity-controlled analysis and given the risk of residual
confounding, a randomized trial is required to definitively address this
issue. We also agree that the results of patients in the single-treatment
multivessel arm may be “biased” because of peri-procedural compli-
cations; however, as we also pointed out in the article, some of these
procedures may have been instigated by a more complex and lengthy
single procedure, such as contrast nephropathy, which might have
been avoided with a more judiciously staged procedure strategy. Thus,
these data were consistent with the current American Heart Associ-
ation/American College of Cardiology and European Society of
Cardiology guidelines to only treat the infarct artery, pending the
results of a more definitive randomized controlled trial. Finally, we are
preparing a paper about the effects of multivessel versus single-vessel
disease, the results of which are forthcoming.
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